Protein Isoform Determination
Protein isoforms
Posttranslational modification (PTM), like glycosylation, results in a huge number
of protein variants (isoforms) showing micro heterogeneity of different kinds. The
dominating heterogeneity is found in the carbohydrate moieties of glycoproteins.
Other examples are genetic polymorphism, modified functional groups in amino acids
by e.g. phosphorylation, acetylation, or limited proteolysis. No protein seems to
be homogenous and many proteins show a huge number of different isoforms. The distribution
of the isoforms might change due to physiological regulation and pathological processes
and the distribution pattern seems to have high clinical significance. Production
of a typical pattern from one cell-type may affect the whole isoform distribution
in the circulation. The glycosylation of proteins seems to be an important regulator
for the fine-tuning of biological activity. Isoforms show various interactions with
receptors which also can affect their survival time. In cancer, inflammation or
liver diseases, the protein glycosylation pattern is typically changed at an early
stage of the disease. The need for protein isoform detection ranges from high abundance
proteins like haemoglobin (10^-3 M) down to proteins like erythropoietin
(10^-15 M).
Protein isoform determination
The distribution of isoforms seems to have high impact on the biological function
as well as being an indicator of pathological conditions, but the lack of suitable
methods hampers the clinical use of isoform diagnostics.
Few quantitative methods are available for determination of isoforms, especially
for measurement of low concentrations in biological specimens. A combination of
discrete steps of separation (electrophoresis or chromatography) and detection (immunological
technique) is used. The quality of the test depends on the type of specific isoforms
that can be distinguished, how efficiently these isoforms are separated (resolution),
and how well they can be quantified (specificity and sensitivity). The electrophoretic
or chromatographic separations in columns are gentle techniques which do not require
extensive pre-preparation of the biological sample. The advantage with chromatographic
separation is the possibility to use different ligands for isoform separation. Analysis
of the fractions using immunoassay is quantitative, sensitive and specific, although
quite expensive. Slab-gel and capillary electrophoresis separate isoforms due to
charge differences but lack suitable means to quantify and specify correctly. Mass
spectrometry detection does not solve these specificity and quantification problems,
especially not when analysing low abundance glycoproteins. An affinity based pre-treatment
step that specifically captures the protein of interest and concentrates it in relation
to other proteins will enhance the possibilities to use these types of methods.
None of the available techniques is suitable for high-throughput testing or for
point-of-care applications. The chromatographic approach, utilizing selected ligands
for separation, in combination with immunoassay seems to be the best way for quantitative
isoform detection but a miniaturisation is needed.
Urgent need for better methods for isoform analysis
Several interesting and valuable analytes appear in low concentrations and show
extensive micro-heterogeneity which causes variable results when using available
test kits. Prostate specific antigen (PSA), about 100 pM in serum, appears mainly
in complexes with other proteins. It shows degradation products and differences
in the carbohydrate chains and should be a better marker for prostate cancer if
the relevant isoform pattern, including glycoforms, could be determined. Cardiac
troponin I (cTnI), about 3 pM in serum, is released into the circulation after myocardial
injury (MI). It appears in complexes with other proteins, and may undergo both oxidation
and phosphorylation as well as proteolysis after release. cTnI is a marker with
wide diagnostic window, but abnormal levels appear late after the onset of MI. The
isolated measurement of early released non-degraded isoforms will most probably
result in earlier diagnosis. Erythropoietin (EPO), about 0.3 pM in urine, is a glycoprotein
hormone with about 40% carbohydrate and probably several hundreds of isoforms appearing
in normal samples, and as such, a challenging analyte. Methods for identification
of aberrant EPO isoform profiles have been developed for identification of illegal
use of recombinant EPO, which enhances the performance during sport competitions.
Profiles of differently charged EPO isoforms can be shown by column electrophoresis
combined with sensitive immunoassay quantification of the fractions. The presently
accredited EPO doping test is using isoelectric focusing and a double immunoblotting
technique. These tests take several days to perform and are very expensive.
Development of new methods
MAIIA (Membrane Assisted Isoform ImmunoAssay) is a novel lab-on-a-chip based technology
for rapid and sensitive measurement of protein isoforms in biological specimens.
The chromatographic zone can be provided with suitable ligands, such as lectins
and receptors, as well as charged ones, and the porous monolith shows excellent
chromatographic properties. The technology has been utilized to show the transferrin
isoform profile, to measure carbohydrate-deficient transferrin as well as to distinguish
low amounts of recombinant and endogenous EPO present in urine. The MAIIA technology
seems to fulfil the requirements as a rapid and sensitive isoform determination
method with potential to resolve and detect several types of PTM isoforms even when
they appear in the femto-molar (10^-15 M) concentration range.